๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Evaluation of safety and tolerance in clinical trials with antimicrobial agents

โœ Scribed by H. Lode; R. Stahlmann

Publisher
Springer
Year
1990
Tongue
English
Weight
441 KB
Volume
9
Category
Article
ISSN
0934-9723

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Adalimumab safety in global clinical tri
Adalimumab safety in global clinical trials of patients with Crohn's disease
โœ Jean-Frรฉdรฉric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson; ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 145 KB ๐Ÿ‘ 2 views

Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr

Evaluation of cancer screening programs.
Evaluation of cancer screening programs. Parallels with clinical trials
โœ Dr. Aristide Apostolides; Maureen Henderson ๐Ÿ“‚ Article ๐Ÿ“… 1977 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 586 KB

The methodologic limitations of available observational evidence for the evaluation of ongoing cancer control programs is reviewed. The specific example of Control Programs for Cervical Cancer is chosen to illustrate these limitations. These limitations pertain to the special features of the natural